CD274 and non-small cell lung carcinoma: According to a recent analysis18, the ORR to Nivolumab in a group of 511 NSCLC patients with PD-L1 positive tumors ranges from 16% to 50%, confirming that PD-L1 in tumor tissues represents a very imperfect biomarker.